Navigation Links
Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Date:2/24/2011

CRANBURY, N.J., Feb. 24, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the pricing of its underwritten public offering of 23,000,000 units, consisting of 23,000,000 shares of its common stock, Series A Warrants to purchase 2,000,000 shares of its common stock and Series B Warrants to purchase 21,000,000 shares of its common stock, at a price to the public of $1.00 per unit. Palatin expects that the net proceeds of the offering will be approximately $21,100,000 after deducting underwriting discounts and commissions and other estimated offering expenses.

Each unit consists of one share of common stock, a Series A Warrant exercisable for 0.087 of a share of common stock at an initial exercise price of $1.00 per share and a Series B Warrant exercisable for 0.913 of a share of common stock at an initial exercise price of $1.00 per share. The Series A Warrants are exercisable immediately upon issuance and expire on the fifth anniversary of the date of issuance.  The Series B Warrants are exercisable beginning one year and one day from the date of issuance, but only if Palatin's stockholders increase the number of its authorized shares of common stock, and expire on the fifth anniversary of the date they first become exercisable.

The offering is expected to close on or about March 1, 2011, subject to the satisfaction of customary closing conditions.

Roth Capital Partners is acting as sole book-running manager for the offering and Madison Williams and Company is acting as co-manager.

Palatin intends to use the proceeds from this offering for general corporate purposes and working capital, including its clinical trial program with bremelanotide for female sexual dysfunction, and secondarily for its PL-3994 development programs for asthma and a development program for new peptides for sexual dysfunction.

The units are
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
2. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
3. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
5. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
6. Palatin Announces Strategic Realignment of Operations
7. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
8. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
9. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... to Host Conference Call at 12:30 p.m. Eastern Time, September 19, ... ... Sept. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that ... obtained the,United States rights to SANCTURA(R) and SANCTURA(R) XR. In connection with,Allergan,s ...
... Corporation,(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company ... M.D., has been appointed,President and Chief Executive Officer, ... remain with the Company through the end,of 2007, ... on CuraGen,s,Board of Directors until the Annual Stockholders ...
... for ... inflammatory bowel disease., OKLAHOMA CITY, Sept. 18 Altheus Therapeutics, ... trials,testing the efficacy of its therapy for the treatment of inflammatory ... by the,Oklahoma Seed Capital Fund and Oklahoma Equity Partners. About ...
Cached Biology Technology:Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 2CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 3CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 4CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 5Altheus Therapeutics Secures $3.6 Million in Venture Capital 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... A major step in commercializing the groundbreaking research ... University of Minnesota signed an exclusive, global license agreement ... worldwide attention in 2008 when her team announced that ... laboratory. The technology licensed to Miromatrix holds the ...
... Calif., Feb. 16, 2010 Butterfly experts have suspected for ... in explaining wing color diversity. Now, for the first time, ... at least in nine Heliconius species. ... ultraviolet colors also have UV-yellow pigment on their wings, reports ...
... coastal fog has decreased significantly over the past 100 years, ... according to a new study by University of California, Berkeley, ... a natural cycle of the result of human activity, but ... entire redwood ecosystem, the scientists say. , "Since 1901, the ...
Cached Biology News:U of Minnesota finalizes license agreement to form start-up company based on Doris Taylor research 2Butterfly vision, wing colors linked, UCI study finds 2Fog has declined in past century along California's redwood coast 2Fog has declined in past century along California's redwood coast 3Fog has declined in past century along California's redwood coast 4